This report provides an in-depth company profile for Mediceo Paltac Holdings Co Ltd ranked 388th in the 2006 Fortune Global 500. All data is gathered from primary source. Reports are available i ...
IntroductionFor 25 years, blockbusters have played a key role in driving strong drug market growth. However, pressure on blockbusters is increasing, as both regulators and payers are shifting away ...
Partneringreview 2006 Financing Public offering provides an in depth view into the public offering focused financings announced in 2005, in a clear and accessible format. The report analyzes d ...
The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key ...
Pour réussir votre approche de ce marché dont les importations aussi bien de matières premières que de produits finis sont en hausse, vous disposerez dans ce guide-répertoire d'un bref panorama du mar ...
Snapshots International | 13 pages | September 2006 | English
Ukraine Pharmaceuticals 2006 provides 2005 year-end market size data, with 2006 estimates, 4 years of historical data and five-year forecasts. The report gives an instant overview of the Ukrainian ...
Snapshots International | 13 pages | August 2007 | English
Snapdata's Snapshots Poland Pharmaceuticals 2007 provides 2005 year-end market size data, with 2006 estimates, 4 years of historical data and five-year forecasts. The Snapshots report gives an inst ...
Datamonitor's Onyx Pharmaceuticals, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business struc ...
Datamonitor's Pharmaceuticals in Singapore industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size ...
IntroductionTrimeris is a biopharmaceutical company having the credit of successfully developing first fusion inhibitor: FUZEON, representing the first new class of anti-HIV treatments in seven years. ...